AvKare recalled 2,003 cartons of Chlorpromazine Hydrochloride Tablets on August 25, 2025. The recall stems from the presence of a foreign substance in the medication. Consumers should stop using the product immediately and seek guidance from healthcare providers.
Presence of a foreign substance.
Consumers and healthcare providers should stop using this product immediately. Contact AvKARE or your healthcare provider for guidance. Notification method: E-Mail
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Chlorpromazine Hydrochloride Tablets, USP, 100 mg, packaged in 50-tablet cartons. Lot numbers include 47089 and 47604, with expiration dates of December 31, 2025, and March 31, 2026. The medication was distributed nationwide in the USA.
The recall is classified as Class II due to the potential health risks associated with the presence of a foreign substance in the tablets. This could pose a serious health risk to consumers.
There are no reported incidents or injuries associated with this recall at this time. Consumers are advised to discontinue use as a precaution.
Consumers should stop using the recalled Chlorpromazine Hydrochloride Tablets immediately. Contact AvKARE or consult a healthcare provider for further guidance on the recall.
For more information, consumers can email AvKARE or visit their website. The FDA recall notice can also be found at the provided link.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.